3-D QSAR studies on new dibenzyltin(IV) anticancer agents by comparative molecular field analysis (CoMFA)

Bioorg Med Chem Lett. 2002 Jan 7;12(1):61-4. doi: 10.1016/s0960-894x(01)00684-9.

Abstract

Dibenzyltin(IV)dichloride and dibenzyltin(IV)diisothiocyanate derivatives with N,S-donor ligands show significant cytotoxic activities against human cancer cell lines, and are well compared to analogous dialkyltin(IV) derivatives. CoMFA models were generated for the first time for these organotin derivatives using the cytotoxic activities (against two human tumor cell lines, MCF-7, a mammary carcinoma and WiDr, a colon carcinoma) of 21 complexes. High r(2) and r(2)(cv) values for both CoMFA models indicate good predictive power for the models.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / toxicity
  • Benzyl Compounds / chemistry*
  • Benzyl Compounds / pharmacology
  • Benzyl Compounds / toxicity
  • Cell Death / drug effects
  • Drug Evaluation, Preclinical
  • Humans
  • Ligands
  • Mice
  • Models, Molecular
  • Organotin Compounds / chemistry*
  • Organotin Compounds / pharmacology
  • Organotin Compounds / toxicity
  • Quantitative Structure-Activity Relationship*
  • Tumor Cells, Cultured / drug effects

Substances

  • Antineoplastic Agents
  • Benzyl Compounds
  • Ligands
  • Organotin Compounds
  • dibenzyltin dichloride